Skip to main navigation

menu

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Extras Menu

Media resources
Contact us

Aclaris - Corp Menu

About Us »
« Back
Research and Development »
« Back
Partnerships
Careers
Citizenship »
« Back
- Scientist Development Program
- Aclaris Support
Investors »
« Back

Aclaris - Investor Relations

Investor Overview
Stock Information
Press Releases
Events
SEC Filings
Corporate Governance
Investor Presentations
Investor FAQs
Email Alerts

Investor Contact

For investor related questions, please email

investors@aclaristx.com

Investor Overview

Stock quote

VOLUME:

View stock performance »

Minimum 15 minutes delayed. Source: LSEG

Investor Overview

Press Releases

March 20, 2026

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

March 18, 2026

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

March 3, 2026

Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference

Events

Mar 10, 2026
1:40 PM EDT

Leerink Global Healthcare Conference

Feb 26, 2026
8:40 AM EST

Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 12, 2026
2:30 PM EST

Guggenheim Emerging Outlook: Biotech Summit 2026

Feature Presentation

Corporate Update Presentation

March 2026 Corporate Overview

Aclaris - Footer Menu

Terms of Use
Privacy Policy
Contact Us
Fraudulent Activity Notice

© 2026 Aclaris Therapeutics, Inc. All rights reserved. Unless otherwise noted, all trademarks referenced on this page are owned by Aclaris Therapeutics.